NCT03978039 National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group
| NCT ID | NCT03978039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Bergonié |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 150,000 participants |
| Start Date | 2010-01-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150,000 participants in total. It began in 2010-01-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas \[RESOS\] / French expert network dedicated to the pathology of sarcomas \[RREPS\]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas \[NETSARC\]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples. Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes. With the financial support of the French National Cancer Institute \[Institut National du cancer \[INCa\]).
Eligibility Criteria
Inclusion criteria : * Diagnosis of sarcoma * Diagnosis in a French Comprehensive Cancer Center * Any age
Contact & Investigator
Maud Toulmonde, MD
STUDY CHAIR
Institut Bergonié, Bordeaux, France
Frequently Asked Questions
Who can join the NCT03978039 clinical trial?
This trial is open to participants of all sexes, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03978039 currently recruiting?
Yes, NCT03978039 is actively recruiting participants. Contact the research team at m.toulmonde@bordeaux.unicancer.fr for enrollment information.
Where is the NCT03978039 trial being conducted?
This trial is being conducted at Bordeaux, France, Lyon, France, Villejuif, France.
Who is sponsoring the NCT03978039 clinical trial?
NCT03978039 is sponsored by Institut Bergonié. The principal investigator is Maud Toulmonde, MD at Institut Bergonié, Bordeaux, France. The trial plans to enroll 150,000 participants.